XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Net Income (Loss) Per Share Attributable to Common Shareholders (Tables)
9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Schedule of basic and diluted net loss per share
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2021   2020   2021   2020 
Numerator :                
Net income (loss) attributable to common shareholders – Basic  $28,944   $(10,295)  $(14,163)  $(20,055)
Less interest expense on potentially dilutive convertible notes payable  $196   $-   $-   $- 
Net income (loss) attributable to common shareholders - Diluted  $29,140   $(10,295)  $(14,163)  $(20,055)
                     
Denominator:                    
Weighted average common shares outstanding –Basic   62,071,754    17,358,159    61,307,699    17,358,159 
Weighted average effect of potentially dilutive securities:                    
Effect of potentially dilutive stock options   5,791,023    
-
    
-
    
-
 
Effect of potentially dilutive common stock warrants   1,485,049    
-
    
-
    
-
 
Effect of potentially dilutive convertible notes payable   482,703    
-
    
-
    
-
 
Effect of potentially dilutive restricted stock awards   208,105    
-
    
-
    
-
 
Weighted average common shares outstanding –Diluted   70,038,634    17,358,159    61,307,699    17,358,159 
                     
Net income (loss) per share attributable to common shareholders:                    
Basic  $0.47   $(0.59)  $(0.23)  $(1.16)
Diluted  $0.42   $(0.59)  $(0.23)  $(1.16)

 

Schedule of securities excluded from computation of diluted net income (loss) per share
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2021   2020   2021   2020 
Series D redeemable convertible preferred stock   
-
    9,394,057    
-
    9,394,057 
Series C redeemable convertible preferred stock   
-
    7,264,519    
-
    7,264,519 
Series B redeemable convertible preferred stock   
-
    4,168,815    
-
    4,168,815 
Series A redeemable convertible preferred stock   
-
    16,066,503    
-
    16,066,503 
Series D redeemable convertible preferred stock warrants   
-
    320,441    
-
    320,441 
Series A redeemable convertible preferred stock warrants   
-
    1,608,670    
-
    1,608,670 
Convertible notes payable (see Note 11)   
-
    
-
    482,703    
-
 
Common stock warrants (see Note 10)   2,523,351    
-
    4,569,962    
-
 
Options to purchase common stock   2,685,575    7,509,810    9,063,423    7,509,810 
Restricted stock awards   1,100,050    
-
    1,245,489    
-
 
Chardan Unit Purchase Option Warrants (see Notes 3 and 10)   24,583    
-
    24,583    
-
 
Clene Nanomedicine contingent earn-out shares (see Note 3 and 12)   8,346,185    
-
    8,346,185    
-
 
Initial Shareholders contingent earn-out shares (see Note 3 and 12)   750,000    
-
    750,000    
-
 
Total   

15,429,744

    46,332,815    24,482,345    46,332,815